New antibody combo aims to fight Hard-to-Treat cancers

NCT ID NCT07158918

Recruiting now Disease control Sponsor: ABL Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing a new experimental drug called ABL103, given together with the approved immunotherapy pembrolizumab (Keytruda) and sometimes a chemotherapy called taxane. The study includes 65 adults with advanced or metastatic solid tumors that have worsened after standard treatments. The main goals are to check safety and see if the combination can shrink or control the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABL103 (a bispecific antibody) combined with pembrolizumab (Keytruda) and optionally a taxane chemotherapy
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1/2 trial with only 65 participants, so results may not apply to all patients. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Asan Medical Center
NOT_YET_RECRUITING

Seoul, 05505, South Korea
PASO Medical
NOT_YET_RECRUITING

Frankston, Victoria, 3199, Australia
Samsung Medical Center
NOT_YET_RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
UH Cleveland Medical Center
NOT_YET_RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.